| Expression pattern: |
DN |
| Associated gene: |
LC3II/I, GPX4 |
| Associated microRNA: |
- |
| Biological function: |
Reverses chemoresistance and enhances chemosensitivity by promoting autophagy-dependent ferroptosis; increases apoptosis; decreases cell viability/IC50 under doxorubicin. |
| Molecular mechanism: |
circRNA encodes a 109-aa peptide (circ_0004872-109aa) that promotes autophagy-dependent ferroptosis (mitophagy/LC3 changes, increased Fe2+/ROS/lipid peroxidation; inhibited by 3-MA), thereby overcoming doxorubicin chemoresistance; delivered via NGR-modified CAF-derived exosomes. |
| Biological pathway or process: |
ferroptosis (promotes); autophagy (promotes); apoptosis (promotes); drug resistance (inhibits) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; Bioinformatics Analysis; Transfection; RT-qPCR; CCK8; Annexin V/PI Flow Cytometry; Luciferase Reporter Assay; Western Blot; LC-MS/MS; IF (Immunofluorescence); In Vivo Animal Model; TUNEL; H&E Staining |
| Clinical significance: |
- |
| Description: |
In doxorubicin-resistant osteosarcoma cells, hsa_circ_0004872 is down-regulated, and restoring it (or its encoded 109-aa peptide) increases chemosensitivity. Mechanistically, the circRNA-encoded peptide promotes autophagy-dependent ferroptosis (with increased ferroptosis markers and LC3 changes), thereby reversing chemoresistance; targeted delivery is achieved via NGR-modified CAF-derived exosomes. |
| Confidence score: |
0.6966 |